Next Article in Journal
Distribution and Molecular Characterization of β-Glucans from Hull-Less Barley Bran, Shorts and Flour
Previous Article in Journal
Zeranol Down-Regulates p53 Expression in Primary Cultured Human Breast Cancer Epithelial Cells through Epigenetic Modification
Previous Article in Special Issue
In Silico Theoretical Molecular Modeling for Alzheimer’s Disease: The Nicotine-Curcumin Paradigm in Neuroprotection and Neurotherapy

Int. J. Mol. Sci. 2011, 12(3), 1533-1562; doi:10.3390/ijms12031533

Review
Mechanisms of Estrogens’ Dose-Dependent Neuroprotective and Neurodamaging Effects in Experimental Models of Cerebral Ischemia
Jakob O. Strom 1,*, Annette Theodorsson 1,2 and Elvar Theodorsson 1
1
Department of Clinical and Experimental Medicine/Clinical Chemistry, Linkoping University, SE-581 83 Linköping, Sweden; E-Mails: annette.theodorsson@liu.se (A.T.); elvar.theodorsson@liu.se (E.T.)
2
Department of Clinical and Experimental Medicine/Neurosurgery, Linkoping University, University Hospital, SE-581 85 Linkoping, Sweden
*
Author to whom correspondence should be addressed; E-Mail: jakob.strom@liu.se; Tel.: +46-73-9560108; Fax: +46-010-1033240.
Received: 17 August 2010; in revised form: 10 February 2011 / Accepted: 22 February 2011 /
Published: 25 February 2011

Abstract

: Ever since the hypothesis was put forward that estrogens could protect against cerebral ischemia, numerous studies have investigated the mechanisms of their effects. Despite initial studies showing ameliorating effects, later trials in both humans and animals have yielded contrasting results regarding the fundamental issue of whether estrogens are neuroprotective or neurodamaging. Therefore, investigations of the possible mechanisms of estrogen actions in brain ischemia have been difficult to assess. A recently published systematic review from our laboratory indicates that the dichotomy in experimental rat studies may be caused by the use of insufficiently validated estrogen administration methods resulting in serum hormone concentrations far from those intended, and that physiological estrogen concentrations are neuroprotective while supraphysiological concentrations augment the damage from cerebral ischemia. This evidence offers a new perspective on the mechanisms of estrogens’ actions in cerebral ischemia, and also has a direct bearing on the hormone replacement therapy debate. Estrogens affect their target organs by several different pathways and receptors, and the mechanisms proposed for their effects on stroke probably prevail in different concentration ranges. In the current article, previously suggested neuroprotective and neurodamaging mechanisms are reviewed in a hormone concentration perspective in an effort to provide a mechanistic framework for the dose-dependent paradoxical effects of estrogens in stroke. It is concluded that five protective mechanisms, namely decreased apoptosis, growth factor regulation, vascular modulation, indirect antioxidant properties and decreased inflammation, and the proposed damaging mechanism of increased inflammation, are currently supported by experiments performed in optimal biological settings.
Keywords:
estrogen; cerebral ischemia; stroke; animal experiments; administration methods

1. Introduction

In the 1990s, several studies demonstrated neuroprotective effects of estrogens in animal models of cerebral ischemia [13]. This supported a hypothesis of estrogen neuroprotection that earlier had been postulated from the clinical observation that women are less likely to suffer from stroke compared to men, and that this protection diminishes by the advent of menopause [4]. Several previous epidemiological studies had also corroborated this hypothesis by indicating decreased stroke incidence in women on hormone replacement therapy [4]. Encouraged by the potential of estrogens as a mean of preventing illnesses including stroke and other cardiovascular diseases, substantial research efforts have been invested in further studies of the matter. However, later studies have been contradictory regarding estrogens’ effects on stroke, exemplified by the large randomized controlled trial Women’s Health Initiative, which was interrupted prematurely because of increased incidences of breast cancer, stroke and cardiovascular disease, thus apparently antagonizing the hypothesis that estrogens are neuroprotective (it requires mention that in the case of this study conjugated equine estrogens were used, and not 17β-estradiol that has been used in most animal trials) [5].

A few animal studies also reported increased ischemic damage from estrogens [611], in contrast to a large number of experiments in which neuroprotection was found [1214]. This dichotomy concerning estrogens’ effects in animal models of cerebral ischemia was analyzed in a recent systematic review of rat studies, designating the dose and mode of estrogen administration as the culprits [15], which was later experimentally confirmed [16]. Slow-release pellets for subcutaneous implantation produced by the company IRA (all abbreviations are listed above) was identified as the only mode of estrogen administration which has led to increased ischemic lesions, plausibly due to the prolonged, supra-physiological plasma concentration peak (300–600 pg/mL, in comparison to the physiological 5–65 pg/mL) which characterizes these implants [17]. This is well in line with the concept of hormesis, stating that steroid hormones can have diametrically different actions in different concentration ranges [18]. The fact that estrogens seem to exert their effects via several different pathways, such as the classical nuclear receptors ER-α and ER-β, membrane-linked receptors and through direct molecular mechanisms further adds to the complexity, and could account for the hormesis phenomenon. The highest dosed pellets were in the abovementioned systematic review found to be most neurodamaging, while pellets containing lower doses of estrogens were more likely to be protective. The two other main methods of administering estrogens to rats; subcutaneous silastic capsules (generated serum concentrations of 40 pg/mL diminishing to 5 pg/mL in 42 days [17]) and subcutaneous injections (generated baseline 17β-estradiol concentrations of 10–110 pg/mL [17]), showed consistent neuroprotection in the doses tested (Table 1) [15].

Concerning mechanisms of estrogens’ effects in cerebral ischemia, there have been numerous explanations, mainly focusing on estrogens’ protective properties, but also with some suggestions of detrimental pathways. In the following sections, we will review the five most extensively investigated potential neuroprotective mechanisms, namely decreased oxidative stress (Section 2.1) decreased inflammation (2.2), decreased apoptosis (2.4), growth factor regulation (2.5) and vascular modulation (2.6), and the three suggested neurodamaging mechanisms increased oxidative stress (2.1), increased inflammation (2.2) and increased excitotoxicity (2.3). Each section consists of a brief summary of data supporting the mechanism hypothesis, when required also with a complementary description of pathways. Subsequently the estrogen administration methods used and in the cited studies are described, and it is discussed how well this matches with the notion that estrogens are protective in physiological doses and damaging in very high doses. Concerning the actual serum estrogen concentrations in the cited studies, it is unfortunately very uncommon that researchers do measurements of 17β-estradiol on more than one occasion during an experiment. Concentrations measured in a single blood sample provide very little information about the serum concentrations at the other time-points of the study. Therefore, presenting the (in the vast majority of cases) single measurements from the studies cited run the risk of misleading the reader and is therefore not done here. Further, analysis of minute amounts of 17β-estradiol, most often performed with radioimmunoassay, should—because of the difficulties in calibrating the methods and the large inter-assay variations—always be performed including serum from native, cycling female rats to obtain reference intervals, which sadly is even rarer [32]. However, it is important to bear in mind that even if blood levels are monitored, these only represent a crude estimate of the concentrations in the brain, where the actual effects take place.

In vitro experiments are cited throughout the review, although it should be noted that the concentrations of estrogens used are generally several orders of magnitude higher than in whole-animal experiments and therefore hard to interpret to in vivo conditions. Interestingly, the dose-dependent dichotomy of studies reporting protective versus damaging results found in whole-animal experiments is not found in cell culture experiments.

Although not reviewed below, a number of additional suggested protective mechanisms also deserve mention, even though research efforts into their pathways are still in early stages. These include increased recruitment of stem cells from the subventricular zone [33], avoidance of apoptosis by balancing phosphatase activity [34] and decrease of excitotoxicity by reducing NMDA-signaling (please note that the opposite; that estrogens may increase excitotoxicity and thereby increase ischemic damage, is reviewed under 2.3) [35,36]. A simplified map of pathways and actions of estrogens that have been postulated to influence cerebral ischemia in a protective or detrimental direction is presented in Figure 1.

2. Mechanisms for Estrogens’ Neuroprotective and Neurodamaging Effects

2.1. Decreased and Increased Oxidative Stress as Mechanisms of Estrogen Neuroprotection and Neurodamage

Oxidative stress is an important mechanism in cellular damage in general and cerebral ischemia in particular. Ischemia prompts mitochondria to produce ROS, which causes direct damaging oxidative reactions such as lipid peroxidations, as well as triggering apoptotic cascades. The cell has intricate defense systems against oxidative damage, including scavenging activity by SOD, glutathione peroxidase, and catalase, and further detoxification by small molecules such as glutathione, ascorbic acid, and α-tocopherol. However, during cerebral ischemia, especially reperfusion, these systems are generally overrun by the massive oxidative stress [44]. Estrogens have been stipulated to exert their neuroprotective effects both through direct chemical effects and indirectly via upregulation of the cell’s anti-oxidative defense mechanisms (Figure 1) [34].

2.1.1. Direct Anti-Oxidative Effects

Direct anti-oxidative effects have been found in several studies. More specifically, estrogens have been reported to prevent intracellular peroxide accumulation in an ER-independent manner [45], decrease ROS production [46], limit lipid peroxidation [4750], protect against oxidative stress FeSO4 [51], and to decrease hydrogen peroxide concentrations [30]. In one of these studies, no extra protection was afforded by adding known potent free radical scavengers, indicating that estrogens exert all the protective effects available through anti-oxidative mechanisms [48]. Further, 17α-estradiol, a less feminizing enantiomer of 17β-estradiol, has been shown to protect against glutamate and hydrogen peroxide stress to a similar extent as 17β-estradiol, indicating the importance of receptor-independent pathways [52]. Anti-oxidative mechanisms have also been suggested merely on the basis that estrogens can protect against oxidative stress, although it should be emphasized that protection against an oxidative assault is not necessarily dependent on a primary anti-oxidative mechanism [53,54]. A further mechanism for estrogens’ direct anti-oxidative effect was proposed by Prokai et al., providing evidence that estrogens can engage in a redox cycle in which estrogens turn into a quinol when eliminating a radical, to subsequently be converted back to the parent estrogen using NADPH as a reducing agent [55,56]. Interestingly, it was demonstrated that the quinol-cycling actually made the compound function as a prodrug that was selectively activated in the brain, importantly without uterotropic actions [55]. 17β-estradiol’s anti-oxidative effect has also been attributed to the hydroxyl group in the C3 position of the A ring, even though one study found no protection by neither of 2-hydroxyestradiol nor 2-methoxyestradiol, despite the fact that these estrogen metabolites have intact hydroxyl groups [57]. However, the last-mentioned study is difficult to assess because of possible differences in brain-uptake by the three compared compounds, and further, in another article it is on the contrary reported that 2-methoxyestradiol protects against ischemia [58].

Taken together, the current evidence indicates that estrogens exert direct anti-oxidative effects under certain circumstances. However, it requires emphasis that the genomic and non-genomic actions of estrogens are impossible to firmly separate, especially in vivo. Also, an important concern is that the abovementioned studies mainly have been performed in vitro and using hormone concentrations that are extremely high (in the magnitude of 0.1–100 μM) compared to what is normally achieved in animal models of cerebral ischemia [15,45,46,49,50]. An exception, which seems to support the anti-oxidative evidence, is a study by Kii et al., in which estrogens were shown to decrease levels of hydrogen peroxide measured by microdialysis, which were not decreased by tamoxifen in a rat model of cerebral ischemia [30]. However, the results of this study remain to be confirmed in studies less fraught with assessment difficulties. Since estrogens are protective in cerebral ischemia only within a relatively narrow and low range of concentrations, studies showing the part played by estrogens anti-oxidative effects in physiological concentrations in vivo remain to be done. Thus, although estrogens are likely neurodamaging in high concentrations, even much higher levels, only relevant in cell cultures, seem to be required to produce the direct anti-oxidative effects of estrogens.

2.1.2. Indirect Anti-Oxidative Effects

Indirect anti-oxidative effects of estrogens have been reported including attenuation of microglial superoxide release [59], increase of glutathione reductase, gamma-glutamylcystein synthetase, glutaredoxin and glutathione [6064], increased MnSOD activity [65,66] and expression [67,68], upregulation of Cu/Zn SOD expression [67], reduction of free radical production via an increase mitochondrial efficiency [69,70], attenuation of NADPH oxidase activation [71,72] and decrease of the oxidative stress marker nitrotyrosine [67]. These effects have been found to at least in part result from nuclear ER-mediated upregulation of anti-oxidative proteins [34].

In contrast to the direct anti-oxidative mechanisms presented in the above section, these examples of upregulation of the oxidative defense system has been demonstrated in many studies in relevant biological contexts, such as mice and rats receiving subcutaneous and intraperitoneal injections [64,67,6971]. Thus, at present the proposed indirect anti-oxidative mechanisms seem more likely to be relevant in actual whole-animal cerebral ischemia models than the direct anti-oxidative mechanisms do.

2.1.3. Pro-Oxidative Effects

As aforementioned, estrogens have also been shown to increase oxidative stress, and thereby possibly augment ischemic damage (Figure 1) [9,73]. The reported pro-oxidative effects include increased mitochondrial ROS production [74,75], oxidative DNA-damage in sperm and ovarian surface epithelium [76,77], reduced levels of anti-oxidant proteins in rat brain [78], promotion of oxidative damage in rat liver cells [79] and increased ROS-production from the estrogen metabolites 2-methoxyestradiol and 4-hydroxyestradiol [8082]. However, these pro-oxidative effects of estrogens have mainly been reported from in vitro experiments and in other tissues than the brain, while studies on the nervous system almost uniformly have found estrogens to exert anti-oxidant properties [73]. This could possibly reflect tissue-specific estrogen response patterns, which has been proposed to result from differences in cellular balance of ER-β versus ER-α [73].

Apart from a study by Pajovic et al. [78], studies demonstrating pro-oxidative properties of estrogens in a biological context relevant to cerebral ischemia are lacking. In this study, levels of glutathione peroxidase, glutathione-S-transferase and glutathione reductase in male rat brains were decreased in response to moderately dosed exogenous estrogen. Theoretically, this decrease is likely to hamper the cells’ anti-oxidative defense, increasing the risk of ischemia-induced cellular damage [78]. Even taking this study into account, the evidence for estrogenic pro-oxidative actions as a mechanism for increased damage in cerebral ischemia appears scarce, and it cannot be included as a plausible pathway for estrogens’ damaging effects.

2.2. Anti- and Pro-Inflammatory Actions as Mechanisms of Estrogen Neuroprotection and Neurodamage

Cerebral ischemia triggers an acute and prolonged inflammatory process in the brain, characterized by activation of microglia, production of inflammatory cytokines and infiltration of various inflammatory cells, including neutrophils, T-cells and monocytes/macrophages, into the damaged tissue. The inflammatory process is considered an important component of the pathophysiology of stroke, and especially the early inflammatory cell infiltration and cytokine production seem to be predominantly deleterious [83]. Experiments in rats have shown that intraventricular administration of TNF-α, IL-1 and IL-6 exacerbates stroke damage, suggesting a detrimental role of inflammation in the ischemic process [8486]. Further support for this hypothesis is found in the observation that blockage of pro-inflammatory cytokines ameliorates ischemic damage [8691].

2.2.1. Anti-Inflammatory Effects

Anti-inflammatory properties of estrogens have been demonstrated in a large number of studies, and are commonly taken as important mechanisms for estrogens’ neuroprotective effects in stroke [86]. Estrogens have been shown to induce a wide range of anti-inflammatory effects via, for example, reducing leukocyte adhesion [9294], decreasing pro-inflammatory cytokine production [95102], decreasing monocyte activation [103] and altering the microglial activation pattern [104]. Both leukocytes and microglia express ER, offering a direct pathway for estrogens’ actions in inflammatory processes [86], and ER activation is e.g., thought to regulate iNOS transcription [105]. The classical pro-inflammatory cytokines IL-1, IL-6 and TNF-α lack ERE, but are thought to be affected by for example activated ER’s down regulation of nuclear c-Jun and JunD, leading to decreased occupation of AP-1 which in turn could increase the expression of TNF-α (Figure 1) [106].

The studies designed to investigate estrogens’ actions in inflammation have to a large extent been performed in cell cultures, where hormone concentrations are hard to extrapolate to concentrations in intact organisms. Of the studies performed in animals, most have focused on other organs than the brain, which potentially could lead to misinterpretation if the data are extrapolated to estrogens effects in cerebral ischemia. The effects of estrogens on inflammation are in many aspects organ specific, vividly exemplified by the estrogen-induced prostatitis in rats [107] in contrast to the amelioration of soft tissue inflammatory conditions [108]. To elucidate at which estrogen concentrations anti-inflammatory effects in the brain occur, we here narrow our focus to studies performed to assess effect on cerebral inflammation in animals. These are comparatively few, but include experiments that have shown that estrogens limit the activity of the pro-inflammatory transcription factor NFKB in a rat MCAo model [109], decrease leukocyte adhesion both before and after transient forebrain ischemia in rats [92], reduce number of microglia and astrocytes in mice [110], decrease cytokine production in animal models of MCAo [96] and NMDA-induced toxicity [97], block COX-2 activity and PGE2 production after IL-1β administration in rats [102], reduce iNOS activity [105], and decrease monocyte activation and recruitment in response to LPS [103]. In two studies, the importance of anti-inflammation for estrogens’ actions have been demonstrated by the lack of 17β-estradiol neuroprotection in iNOS knockout mice [111] and mice treated with the iNOS inhibitor aminoguanidine [112].

Of these studies, all but two have adopted presumptive low-dose or short-term 17β-estradiol regimes, such as various intraperitoneal or subcutaneous injection schedules and low-dose silastic capsules, which are in the dose range likely to induce protection against ischemic damage [15,92,95,96,102,103,105,109112]. The remaining two of the abovementioned studies used pellets from IRA, which are high-dose regimes capable of inducing either protection or damage in cerebral ischemia [97,110]. In one of the studies using pellets [110], 17β-estradiol merely decreased the number of astrocytes and microglia without relation to stroke, which could be interpreted as a degenerative as well as an anti-inflammatory effect. Further, in the other high-dose pellet study, older rats given the same treatment showed increased cerebral inflammation [97]. Thus, of the studies reporting estrogen-induced decreases in animal brain inflammation, a majority have been performed with short-term or low-dose estrogens similar to regimens that previously have been reported to decrease cerebral ischemic damage, which is as expected if anti-inflammation is one of the actual protective mechanisms [15].

2.2.2. Pro-Inflammatory Effects

Paradoxically, one of the suggested mechanisms for estrogens’ ability to increase damage in cerebral ischemia is the hormones’ pro-inflammatory capacity [7,37]. In several rat experiments, estrogens have been reported to potentiate leukocyte adhesion, increase P-selectin and MPO enzyme activity in cerebral ischemia [7,113], increase TNF-α, TLR-2 and IL-12 in response to LPS stress [114,115], increase IL-1β in a NMDA-toxicity model [97] and to worsen functional outcome in a model of chronic cerebral inflammation (Figure 1) [116].

Most interestingly, in sharp contrast to the majority of studies reporting decreased inflammation, all but one [113] of these studies adopted administration regimens that are likely to produce highly supraphysiological 17β-estradiol concentrations in the range that have been shown to exacerbate ischemic damage in rats [15,17]. The high-dose regimens used were slow-release capsules from IRA [7,97,115] and silastic capsules containing dissolved 17β-estradiol in concentrations about 10 [114] to 250 [116] times higher than the highest dissolved silastic capsule 17β-estradiol concentration that, to the best of our knowledge, has been reported to be neuroprotective [117]. The pro-inflammatory effects of estrogens have generally not been interpreted as resulting from the high hormone dose, but rather as synergistic effects of diabetes [7,113] and old age [97,115,118]. However, a possible contribution of factors such as age and disease do not explain the striking dominance of high-dose regimens in these experiments, thereby suggesting that estrogens in supraphysiological concentrations are likely to have a higher propensity for increasing inflammation, supporting the hypothesis that high-dose estrogens increase damage from cerebral ischemia. It should also be mentioned that estrogens indeed have been reported to protect both diabetic and old animals in several studies, contradicting a clear relation between age, diabetes and neurodamaging effects of estrogens [119123].

2.3. Increased Excitotoxicity as a Mechanism of Estrogen Neurodamage

Excitotoxicity is a well-established feature in cerebral ischemia, and contributes to the pathophysiology by a series of events characterized by abnormal excitation by neurons due to pathological release of excitatory neurotransmitters from damaged cells. In the process, both NMDA and AMPA glutamate receptors are over stimulated, contributing to uptake of Na+, Cl and Ca2+ ions, which depolarizes neurons and leads to subsequent transmitter release, further stimulating receptors in a vicious cycle. The ion uptake leads to cellular edema and to activation of various detrimental Ca2+-dependent enzymes, which in turn damage the cell by degrading cytoskeletal proteins, damaging DNA and by increasing the generation of free radicals [124].

It has been stipulated that estrogens could augment the pathological process in cerebral ischemia by potentiating the excitotoxicity since estrogens have been reported to increase NMDA mRNA in the hippocampal CA1-region [125], increase NMDA-binding sites in CA1 [126,127], increase dendritic spine density or decreased ovariectomy-induced dendritic spine loss in CA1 [126,128130], increased sensitivity of CA1 pyramidal cells to NMDA receptor-mediated synaptic input [126], facilitate seizure activity [131], augment LTP [132,133], increase the excitability of different neurons [134,135], decrease glutamate-uptake by astrocytes [136] and to facilitate kainite induced currents via cAMP-dependant phosphorylation (Figure 1) [137]. It is likely that a substance that facilitates NMDA activity and increases excitability could potentiate excitotoxicity and augment ischemic damage. In line with this hypothesis, it has been reported in several articles that decreased excitotoxicity, either by reducing the number of collaterals [138140] or potentiating GABA-ergic transmission [141,142], is associated with amelioration of ischemic damage.

However, of the many aforementioned studies performed on animals, the vast majority have seen the potentially excitatory effects from low-dose or short-time estrogen administration regimens that are likely to protect from rather than increase ischemic damage [15,17,126,127,129,132,135]. None of the studies adopted the high-dose pellets from IRA that have been shown to be detrimental in cerebral ischemia. Thus it is as yet not established whether estrogens are able to increase excitotoxicity in doses that are relevant to the animal models that have reported increased ischemic damage from estrogens. Also, the abovementioned studies have merely presented indirect evidence of increased excitotoxicity by estrogens. In contrast, several studies have shown decreased excitotoxicity from estrogens in the same dose range (Figure 1) [36,143149]. The studies indicating estrogen-induced increased excitotoxicity have notably largely been restricted to hippocampus, while the ischemic damage in the most common animal stroke model (MCAo) primarily involve the striatum and cerebral cortex.

In conclusion, the hypothesis that estrogens exacerbate ischemic damage by potentiating excitotoxicity has limited support since (1) the potentially excitotoxicity-increasing effects have mainly been demonstrated in experimental paradigms involving presumably neuroprotective hormone regimens; (2) no direct evidence of increased excitotoxicity is as yet available; (3) several studies have reported direct signs of decreased excitotoxicity from estrogen treatment; and (4) the studies reporting excitatory effects have largely been restricted to hippocampus, possibly reflecting site-specific effects.

2.4. Decreased Apoptosis as a Mechanism of Estrogen Neuroprotection

Apoptosis is a major pathophysiological mode of cell death in ischemic brain injury [150,151]. Ischemia triggers mitochondria to produce reactive oxygen species, which do not only directly damage lipids, proteins and nucleic acids in the cell, but also activate various intracellular pathways that return to the mitochondria to induce apoptotic cell death, in part through regulation of pro- and antiapoptotic proteins such as the Bcl-2 family [151]. The Bcl-2 family is an essential group of proteins that regulate the integrity of the mitochondrial membrane, and is subdivided into three subgroups based on structural homology: antiapoptotic proteins including Bcl-2, Bcl-XL and Bcl-w; proapoptotic proteins such as Bax and Bak and the BH3-only proteins including Bad, Bim, Noxa and PUMA [151]. An overweight of pro-apoptotic proteins at the membrane triggers the release of cytochrome c into the cytosol, which in turn combines with Apaf-1 and procaspase-9 to activate various caspases, such as caspase-3. The caspases are the proteins that perform the cellular degradation in apoptosis, exemplified by caspase-3’s cleavage of DNA repair enzymes leading to DNA damage [152]. Another feature of apoptotic cell death is the seemingly mandatory increase in expression of the so-called immediate early genes, such as c-Jun and c-Fos [153,154], which can be used as markers of apoptosis [155]. The importance of apoptosis in stroke is suggested by the neuroprotection afforded by increased expression of the antiapoptotic Bcl-2 [156,157] and by the ischemia-induced upregulation of proapoptotic proteins in animal models of cerebral ischemia [158].

Estrogens have been reported to reduce apoptosis in a number of studies. The antiapoptotic effects of estrogens include blocking the ischemia-induced reduction of Bcl-2 following MCAo [157,159], reducing caspase-3 after global ischemia [160], increasing expression of Bcl-2, Bcl-w and Bcl-XL while decreasing Bax, Bad and Bim [161167], attenuating injury-mediated DNA fragmentation [21], reducing the level of the 120 kDa caspase-mediated spectrin breakdown product [21], decreasing c-Fos induction [155], limiting apoptosis induced by staurosporine in cell cultures [168], inducing cGMP-dependent expression of thioredoxin—a redox protein with potent antioxidative and antiapoptotic properties [169]—and preventing glutamate-induced translocation of cytochrome c from mitochondria to cytosol (Figure 1) [170]. ER activation is also thought to limit apoptosis through increased expression of components in oxidative phosphorylation, making energy production more stable and thus maintaining mitochondrial membrane integrity [34]. Further, Bcl-2 over-expressing male mice sustained smaller infarct sizes compared to their male wild type counterparts, while this difference was not observed in females, which is likely to mean that apoptosis is one of the mechanisms of estrogen neuroprotection [157].

Considering the potential pathways for estrogens’ antiapoptotic actions, it is of interest that the Bcl-2 gene promotor has no ideal consensus sequence for an ERE, but that estrogens can interact with Sp1 for which there are several binding sites in the Bcl-2 gene promoter [171]. Also, estrogens have been shown to induce Bcl-2 expression through STAT3 and phosphoinositide-3-kinase/Akt-dependent CREB, which in turn possibly is activated by GPR-30 [164,168,172]. Akt also targets procaspase-9, members of the Forkhead family of transcription factors, which promote pro-death gene transcription [41]. These increases in antiapoptotic factors compared to proapoptotic factors afforded by estrogens are generally considered to convey neuroprotection by preventing activation of the permeability transition pore, thereby protecting against a cytosolic Ca2+-overload and release of cytochrome c into the cytosol [42,173].

Many of the aforementioned studies have been performed in animal models catering for in vivo relevant dose intervals in which the mechanism occurs. The reported antiapoptotic effects of estrogens presented above have been demonstrated using several different hormone administration protocols, though with an overwhelming dominance of low-dose and/or short-term regimens [15,17,21,155,159,165,166]. This corroborates the combined hypotheses that estrogens are neuroprotective through antiapoptotic mechanisms and that neuroprotection due to estrogens are mainly seen in low dose and/or short-term hormone regimens. However, to our knowledge no study has been performed where estrogens’ influence on apoptosis has been inhibited, and where the effect of such an inhibition has been assessed.

2.5. Growth Factor Regulation as a Mechanism of Estrogen Neuroprotection

Estrogens are known to regulate growth factors, an attribute that has been suggested as another mechanism for the hormones’ beneficial effects in cerebral ischemia [12,41]. Growth factors contribute to improved outcome after cerebral ischemia both by facilitating recovery and by decreasing apoptosis, thereby reducing infarct size [174]. This mechanism overlaps considerably with apoptosis, even if the extensive research focused on estrogens interaction with growth factors merits special attention. Also, the positive, possibly neuroprotective, effects of estrogens on neural cell proliferation, synaptogenesis, modulation of synaptic connectivity and regeneration [175,176] are probably mediated through regulation of growth factors and neurotrophins, including TGF-β, IGF-I, NGF, BDNF and NT-4 (Figure 1) [177182].

17β-estradiol regulates the transcription of numerous growth factor genes through ERs’ binding to ERE in gene promoters. The factors influenced in this manner include, i.e., VEGF [183], TGF-α [184], tau [185], BDNF, NT-4 and NGF [41,179]. ER not only co-localizes with and regulates the expression of neurotrophins and their cognate receptors, but estrogens and neurotrophins also share converging signaling pathways in the MAPK cascade, which includes activation of B-Raf and ERK, in turn regulating a broad array of cytoskeletal and growth-associated genes [186]. Additional evidence implying that estrogens exert their positive effects via growth factor interaction includes the cooperation with IGF-I to exert neuroprotection, possibly by sharing the MAPK and PI3/Akt signaling pathways [177,187]. Interestingly, IGF-I receptor blockade prevents estrogen neuroprotection while the ER antagonist ICI 182,780 can block IGF-I neuroprotection [188,189]. Similar results have been seen in models of cerebral ischemia [41,190], and in another study, a combination of IGF-I and 17β-estradiol did not add any extra protection against ischemia compared to the two substances administered separately [191], emphasizing to the relation between estrogens and growth factors as a protective mechanism in stroke. Moreover, estrogens have been postulated to promote recovery after stroke by directly regulating genes required for growth, such as tau microtubule-associated protein [185], GAP-43, [192], structural lipoproteins such as apolipoprotein E [193], and neurofilament proteins [194].

Thus, ample evidence exists for the notion that estrogens increase the activity of growth factors as a major mechanism for neuroprotection. As expected, the interactions of estrogens with growth factors have been demonstrated in vivo resulting from predominantly low-dose or short term estrogen administration regimens [15,17,178,180,181,187189,192,194]. Thus there is good coherence between the biological environments in which the growth factor interactions have been shown and the notion that estrogens mainly are neuroprotective in physiological concentrations.

2.6. Vascular Modulation as a Mechanism of Estrogen Neuroprotection

The importance of vascular properties, such as vessel wall reactivity and contraction propensity, for the development of stroke is self-evident. Even though this category of factors may seem less important in animal models of cerebral ischemia where the vessel occlusion is artificial, it still influences the crucial aspects of collateral circulation and reperfusion. It is thus likely that increased vasodilatation in the cerebral vascular bed is beneficial in cerebral ischemia by facilitating blood flow to compromised brain regions [39]. The reactivity and contraction propensity of a blood vessel is strongly influenced by locally produced vasodilators including prostacyclin and NO, and vasoconstrictors such as endothelin-1, which in turn are regulated by other factors.

Estrogens have been shown to affect cerebral blood vessels in a number of studies; by relaxing cerebral arteries through inhibition of extracellular Ca2+ influx in vascular smooth muscle [195], moderating thrombotic mechanisms [196], influencing the biosynthesis of prostacyclin [197,198], potentiating ACh-induced endothelium-dependent relaxation [199], enhancing nNOS and eNOS levels [24,200204] and thus increasing NO production [205208], increasing COX-1 levels [200], and by less well characterized pathways which increase cerebral blood flow (Figure 1) [3,22,209212]. It deserves mention that although eNOS could be neuroprotective through vasodilatation, it has also been shown to induce peroxynitrite formation under certain disease states [213], which in turn potentially could compromise cellular viability [214]. Most of these effects, such as influence on eNOS, COX-1 and prostacyclin synthase leading to vasodilatation and improved collateral flow, seem to be exerted via the classical genomic pathway or via the PI3/Akt pathway [39].

Several of the effects of estrogens on the cerebral vasculature have been demonstrated in vivo using estrogen regimens that are in the dose-range likely to mediate neuroprotection [15], such as low-dose subcutaneous injections [24] or physiologically cycling hormones [209]. There are therefore strong indications that estrogens affect important vessel properties in biological contexts relevant for the question of its effect on cerebral ischemia, even though evidence of this mechanism’s indispensability is lacking. Thus, to the best of our knowledge, no study has been performed where estrogens’ impact on blood vessels have been inhibited, and where the effect of such an inhibition has been assessed. Further, numerous studies have been unable to corroborate vascular effects of estrogens in stroke models, notably by absence of blood flow differences before or during MCAo between estrogen treated and estrogen deficient animals, even though differences in stroke outcome were observed [122,215218].

3. Conclusions

3.1. Quality of Mechanism Experiments

Before an overall summary of the mechanisms dealt with here, brief considerations regarding study design, quality and causality may be in place.

In the process of elucidating which mechanisms are important for a certain biological target effect exerted by an investigated substance, different studies obviously contribute evidence of different weight, primarily depending on the experimental design. It is particularly difficult to draw conclusions about causality, exemplified by the fact that decreased/increased inflammatory response and oxidative stress resulting from estrogen supplementation may be a consequence of other mechanisms rather than a primary cause of the decreased/increased damage. Studies investigating mechanisms may be allocated three alternative ranks according to increasing degree of evidence:

  • The lowest degree of “evidence” for a certain mechanism comes from the discovery of a biological alteration, which potentially could bring about the biological target effect, in response to the investigated substance. An example is the finding that estrogens increase the concentration of the synaptic protein syntaxin, which hypothetically (without direct experimental evidence) could facilitate recovery after cerebral ischemia [219].

  • If the investigated substance has an effect on a presumed mechanism that in itself has been proven to exert the biological target effect the evidence is evidently stronger, even if the relative contribution of the mechanism cannot be quantified. An example is the fact that estrogens upregulate Bcl-2 [164], a protein in itself proven to decrease the damage from cerebral ischemia [156,157].

  • A yet higher degree of evidence for a mechanism’s importance is afforded when the presence of a specific blockage inactivates the biological target effect. An example is estrogens’ lack of protective effects in iNOS knocked out mice [111].

Two of the mechanisms of estrogens’ neuroprotection are supported by studies of the highest evidence rank, providing the best evidence for causality between the mechanism and the outcome. These are the abovementioned importance of iNOS [111,112] and the indispensable interactions between IGF-1 and estrogens [41,188191]. Numerous studies in the current field do not reach the highest level of evidence, e.g., due to the lack of a suitable blocker, and thus the weight of the evidence in these studies needs to be adjusted accordingly.

3.2. Summary of Mechanism Evaluations

Decreased apoptosis, growth factor regulation, vascular modulation, indirect decrease of oxidative stress by altering the anti-oxidative defense and decreased inflammation have all been demonstrated in experimental settings fitting the dose-concentration range pattern established for neuroprotection and are thus likely candidates for being true protective mechanisms. Anti-inflammation (iNOS) [111,112], and interaction with growth factors (IGF-I) [41,188191] are due to the abovementioned studies contributing with the highest evidence rank particularly well established. The direct anti-oxidative effect still needs to be demonstrated in relevant biological settings in estrogen concentration intervals known to be protective in whole-animal models, and this mechanism is, as aforementioned, especially difficult to assess because of the difficulties in separating genomic from non-genomic actions.

Of the suggested neurodamaging counterparts, only increased inflammation has been reported to occur under biological settings imitating conditions under which estrogens have been shown to be detrimental in whole-animal stroke experiments, and is thus to date the only real candidate of being a true damaging mechanism. The pro-oxidative effects, with their inherent problem of proving non-genomic actions, have as yet mainly been demonstrated in non-neuronal in vitro trials, and increased excitotoxicity has even less experimental support.

Thus while several mechanisms seem to contribute to the neuroprotective effects of estrogens in lower concentration ranges, it seems that possibly the anti-inflammatory effect of estrogens turning pro-inflammatory in supraphysiological concentrations could explain the observation that estrogens have opposing effects in different concentrations. It should however be emphasized that which mechanisms are true and false as assessed above is a highly complex issue, and that a review of this kind is better viewed as hypothesis-generating than hypothesis-testing.

3.3. Difficulties in Studying the Complex Estrogenic Mechanisms

When reviewing the abundance of studies investigating possible mechanisms of estrogens’ neuroprotective actions, risk of bias is evident in cases when different estrogen effects depending on its concentrations are not taken into account (relating to the concept of hormesis). Effects of estrogens assessed as potentially protective may sometimes just as well be interpreted as risks of increased damage. For example, in a study by Weiland, estrogens were found to increase NMDA binding sites in the hippocampus, which may be taken as a neurotropic effect (protective by facilitating recovery) or as a risk of increased excitotoxicity (harmful in cerebral ischemia) [127]. In another study estrogen replacement decreased the number of astrocytes and microglia in the hippocampus, which was taken as evidence for decreased inflammation instead of the possible alternative assessment that the estrogens induced neurodegeneration [110]. To minimize the risk of similar pitfalls, several controls are needed including e.g., the verification that the biological serum concentrations of estrogens are in the range proven to afford neuroprotection. Unfortunately, careful investigation of the administration methods used are scarce, and in the majority of instances when blood samples are drawn for analysis of serum estrogen levels the sampling is only performed at only one single time point (most often at animal sacrifice), which thus conveys little information of the serum concentrations before and after this specific moment.

3.4. Final Remarks

Investigations of different mechanisms for estrogens’ actions in stroke have been performed in a very wide range of concentrations, profoundly affecting the plausibility of the suggested mechanism given that the hormones’ neuroprotective and neurodamaging properties are in fact restricted to certain dose intervals. In future studies it is crucial that mechanisms are verified in relevant biological contexts where special care has been taken to control estrogen concentrations. This in combination with experimental designs catering for the highest level of evidence will provide the solid ground needed for characterizing estrogens’ actions and pathways in cerebral ischemia.

List of Abbreviations

AChAcetylcholine
AMPAα-Amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
Apaf-1Apoptotic Protein-Activating Factor-1
BDNFBrain-Derived Neurotrophic Factor
BH3Bcl Homology domain-3
CA1Cornu Ammonis area-1
cAMPCyclic Adenosine Monophosphate
cGMPCyclic Guanosine Monophosphate
COXCyclooxygenase
CREBcAMP Response Element Binding protein
eNOSExtracellular Nitric Oxide Synthase
EREstrogen Receptor
EREEstrogen Response Elements
ERKExtracellular signal-Regulated Kinases
GABAGamma-Aminobutyric Acid
GAP-43Growth-Associated Protein-43
GPR-30G-Protein coupled Receptor-30
GSK-3βGlycogen synthase kinase 3β
IGF-IInsulin-like Growth Factor-I
ILInterleukin
iNOSInducible Nitric Oxide Synthase
IRAInnovative Research of America
LPSLipopolysaccharide
LTPLong Term Potentiation
MAPKMitogen-Activated Protein Kinase
MCAoMiddle Cerebral Artery Occlusion
MPOMyeloperoxidase
NADPHReduced form of Nicotinamide Adenine Dinucleotide Phosphate
NFKBNuclear Factor Kappa-light-chain-enhancer of activated B cells
NGFNerve Growth Factor
NMDAN-Methyl-d-Aspartate
nNOSNeuronal Nitric Oxide Synthase
NONitric Oxide
NT-4Neurotrophin-4
PGE2Prostaglandin E2
PI3Phosphatidylinositol-3
PUMAp53-Upregulated Modulator of Apoptosis
ROSReactive Oxygen Species
SODSuperoxide Dismutase
Sp1Specificity Protein-1
STAT3Signal Transducer and Activator of Transcription 3
SVZSubventricular Zone
TGF-αTransforming Growth Factor-α
TLRToll-Like Receptor
TNF-αTumor Necrosis Factor-α
VEGFVascular Endothelial Growth Factor

References

  1. Hall, ED; Pazara, KE; Linseman, KL. Sex differences in postischemic neuronal necrosis in gerbils. J. Cereb. Blood Flow Metab 1991, 11, 292–298. [Google Scholar]
  2. Simpkins, JW; Rajakumar, G; Zhang, YQ; Simpkins, CE; Greenwald, D; Yu, CJ; Bodor, N; Day, AL. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J. Neurosurg 1997, 87, 724–730. [Google Scholar]
  3. Hurn, PD; Littleton-Kearney, MT; Kirsch, JR; Dharmarajan, AM; Traystman, RJ. Postischemic cerebral blood flow recovery in the female: Effect of 17beta-estradiol. J. Cereb. Blood Flow Metab 1995, 15, 666–672. [Google Scholar]
  4. Lobo, RA. The risk of stroke in postmenopausal women receiving hormonal therapy. Climacteric 2009, 12(Suppl 1), 81–85. [Google Scholar]
  5. Rossouw, JE; Anderson, GL; Prentice, RL; LaCroix, AZ; Kooperberg, C; Stefanick, ML; Jackson, RD; Beresford, SA; Howard, BV; Johnson, KC; Kotchen, JM; Ockene, J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. Jama 2002, 288, 321–333. [Google Scholar]
  6. Harukuni, I; Hurn, PD; Crain, BJ. Deleterious effect of beta-estradiol in a rat model of transient forebrain ischemia. Brain Res 2001, 900, 137–142. [Google Scholar]
  7. Yong, Y; Xie, HJ; Zhang, YF; Yang, QD; Liao, DF; Yang, HL; Yan, PK; Liu, ZJ. 17beta-estradiol potentiates ischemia-reperfusion injury in diabetic ovariectomized female rats. Brain Res 2005, 1054, 192–199. [Google Scholar]
  8. Theodorsson, A; Theodorsson, E. Estradiol increases brain lesions in the cortex and lateral striatum after transient occlusion of the middle cerebral artery in rats: No effect of ischemia on galanin in the stroke area but decreased levels in the hippocampus. Peptides 2005, 26, 2257–2264. [Google Scholar]
  9. Gordon, KB; Macrae, IM; Carswell, HV. Effects of 17beta-oestradiol on cerebral ischaemic damage and lipid peroxidation. Brain Res 2005, 1036, 155–162. [Google Scholar]
  10. Carswell, HV; Bingham, D; Wallace, K; Nilsen, M; Graham, DI; Dominiczak, AF; Macrae, IM. Differential effects of 17beta-estradiol upon stroke damage in stroke prone and normotensive rats. J. Cereb. Blood Flow Metab 2004, 24, 298–304. [Google Scholar]
  11. Bingham, D; Macrae, IM; Carswell, HV. Detrimental effects of 17beta-oestradiol after permanent middle cerebral artery occlusion. J. Cereb. Blood Flow Metab 2005, 25, 414–420. [Google Scholar]
  12. Liu, M; Dziennis, S; Hurn, PD; Alkayed, NJ. Mechanisms of gender-linked ischemic brain injury. Restor. Neurol. Neurosci 2009, 27, 163–179. [Google Scholar]
  13. Brown, CM; Suzuki, S; Jelks, KA; Wise, PM. Estradiol is a potent protective, restorative, and trophic factor after brain injury. Semin. Reprod. Med 2009, 27, 240–249. [Google Scholar]
  14. Suzuki, S; Brown, CM; Wise, PM. Neuroprotective effects of estrogens following ischemic stroke. Front. Neuroendocrinol 2009, 30, 201–211. [Google Scholar]
  15. Strom, JO; Theodorsson, A; Theodorsson, E. Dose-related neuroprotective versus neurodamaging effects of estrogens in rat cerebral ischemia: A systematic analysis. J. Cereb. Blood Flow Metab 2009, 29, 1359–1372. [Google Scholar]
  16. Strom, JO; Theodorsson, E; Holm, L; Theodorsson, A. Different methods for administering 17beta-estradiol to ovariectomized rats result in opposite effects on ischemic brain damage. BMC Neurosci 2010, 11, 39. [Google Scholar]
  17. Strom, JO; Theodorsson, E; Theodorsson, A. Order of magnitude differences between methods for maintaining physiological 17beta-oestradiol concentrations in ovariectomized rats. Scand. J. Clin. Lab. Invest 2008, 68, 814–822. [Google Scholar]
  18. Calabrese, EJ; Baldwin, LA. Hormesis: The dose-response revolution. Annu. Rev. Pharmacol. Toxicol 2003, 43, 175–197. [Google Scholar]
  19. Dziennis, S; Jia, T; Ronnekleiv, OK; Hurn, PD; Alkayed, NJ. Role of signal transducer and activator of transcription-3 in estradiol-mediated neuroprotection. J. Neurosci 2007, 27, 7268–7274. [Google Scholar]
  20. Schreihofer, DA; Do, KD; Schreihofer, AM. High-soy diet decreases infarct size after permanent middle cerebral artery occlusion in female rats. Am. J. Physiol. Regul. Integr. Comp. Physiol 2005, 289, R103–108. [Google Scholar]
  21. Rau, SW; Dubal, DB; Bottner, M; Gerhold, LM; Wise, PM. Estradiol attenuates programmed cell death after stroke-like injury. J. Neurosci 2003, 23, 11420–11426. [Google Scholar]
  22. He, Z; He, YJ; Day, AL; Simpkins, JW. Proestrus levels of estradiol during transient global cerebral ischemia improves the histological outcome of the hippocampal CA1 region: Perfusion-dependent and-independent mechanisms. J. Neurol. Sci 2002, 193, 79–87. [Google Scholar]
  23. Sandstrom, NJ; Rowan, MH. Acute pretreatment with estradiol protects against CA1 cell loss and spatial learning impairments resulting from transient global ischemia. Horm. Behav 2007, 51, 335–345. [Google Scholar]
  24. Pelligrino, DA; Santizo, R; Baughman, VL; Wang, Q. Cerebral vasodilating capacity during forebrain ischemia: Effects of chronic estrogen depletion and repletion and the role of neuronal nitric oxide synthase. Neuroreport 1998, 9, 3285–3291. [Google Scholar]
  25. Saleh, TM; Connell, BJ; Legge, C; Cribb, AE. Estrogen attenuates neuronal excitability in the insular cortex following middle cerebral artery occlusion. Brain Res 2004, 1018, 119–129. [Google Scholar]
  26. Plamondon, H; Morin, A; Charron, C. Chronic 17beta-estradiol pretreatment and ischemia-induced hippocampal degeneration and memory impairments: A 6-month survival study. Horm. Behav 2006, 50, 361–369. [Google Scholar]
  27. Choi, YC; Lee, JH; Hong, KW; Lee, KS. 17Beta-estradiol prevents focal cerebral ischemic damages via activation of Akt and CREB in association with reduced PTEN phosphorylation in rats. Fundam. Clin. Pharmacol 2004, 18, 547–557. [Google Scholar]
  28. Yu, SJ; Kim, JR; Lee, CK; Kim, JH; Kam, KY; Hong, JH; Kang, SG. Involvement of purα gene in neuroprotection effects of estrogen in rat ischemic brain model. Korean J. Genet 2006, 28, 403–412. [Google Scholar]
  29. Gulinello, M; Lebesgue, D; Jover-Mengual, T; Zukin, RS; Etgen, AM. Acute and chronic estradiol treatments reduce memory deficits induced by transient global ischemia in female rats. Horm. Behav 2006, 49, 246–260. [Google Scholar]
  30. Kii, N; Adachi, N; Liu, K; Arai, T. Acute effects of 17beta-estradiol on oxidative stress in ischemic rat striatum. J. Neurosurg. Anesthesiol 2005, 17, 27–32. [Google Scholar]
  31. Littleton-Kearney, MT; Klaus, JA; Hurn, PD. Effects of combined oral conjugated estrogens and medroxyprogesterone acetate on brain infarction size after experimental stroke in rat. J. Cereb. Blood Flow Metab 2005, 25, 421–426. [Google Scholar]
  32. Strom, JO; Theodorsson, A; Theodorsson, E. Substantial discrepancies in 17beta-oestradiol concentrations obtained with three different commercial direct radioimmunoassay kits in rat sera. Scand. J. Clin. Lab. Invest 2008, 68, 806–813. [Google Scholar]
  33. Suzuki, S; Gerhold, LM; Bottner, M; Rau, SW; Dela Cruz, C; Yang, E; Zhu, H; Yu, J; Cashion, AB; Kindy, MS; Merchenthaler, I; Gage, FH; Wise, PM. Estradiol enhances neurogenesis following ischemic stroke through estrogen receptors alpha and beta. J. Comp. Neurol 2007, 500, 1064–1075. [Google Scholar]
  34. Simpkins, JW; Yi, KD; Yang, SH. Role of protein phosphatases and mitochondria in the neuroprotective effects of estrogens. Front. Neuroendocrinol 2009, 30, 93–105. [Google Scholar]
  35. Singer, CA; Rogers, KL; Strickland, TM; Dorsa, DM. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci. Lett 1996, 212, 13–16. [Google Scholar]
  36. Weaver, CE, Jr; Park-Chung, M; Gibbs, TT; Farb, DH. 17Beta-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res 1997, 761, 338–341. [Google Scholar]
  37. Carswell, HV; Macrae, IM; Farr, TD. Complexities of oestrogen in stroke. Clin. Sci. (London) 2010, 118, 375–389. [Google Scholar]
  38. Macrae, IM; Carswell, HV. Oestrogen and stroke: The potential for harm as well as benefit. Biochem. Soc. Trans 2006, 34, 1362–1365. [Google Scholar]
  39. Duckles, SP; Krause, DN. Cerebrovascular effects of oestrogen: Multiplicity of action. Clin. Exp. Pharmacol. Physiol 2007, 34, 801–808. [Google Scholar]
  40. Simpkins, JW; Singh, M. More than a decade of estrogen neuroprotection. Alzheimers Dement 2008, 4, S131–136. [Google Scholar]
  41. Lebesgue, D; Chevaleyre, V; Zukin, RS; Etgen, AM. Estradiol rescues neurons from global ischemia-induced cell death: Multiple cellular pathways of neuroprotection. Steroids 2009, 74, 555–561. [Google Scholar]
  42. Arnold, S; Beyer, C. Neuroprotection by estrogen in the brain: The mitochondrial compartment as presumed therapeutic target. J. Neurochem 2009, 110, 1–11. [Google Scholar]
  43. Sherwin, BB. Estrogen therapy: Is time of initiation critical for neuroprotection? Nat. Rev. Endocrinol 2009, 5, 620–627. [Google Scholar]
  44. Fujimura, M; Tominaga, T; Chan, PH. Neuroprotective effect of an antioxidant in ischemic brain injury: Involvement of neuronal apoptosis. Neurocrit. Care 2005, 2, 59–66. [Google Scholar]
  45. Behl, C; Skutella, T; Lezoualc’h, F; Post, A; Widmann, M; Newton, CJ; Holsboer, F. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Mol. Pharmacol 1997, 51, 535–541. [Google Scholar]
  46. Culmsee, C; Vedder, H; Ravati, A; Junker, V; Otto, D; Ahlemeyer, B; Krieg, JC; Krieglstein, J. Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: Evidence for a receptor-independent antioxidative mechanism. J. Cereb. Blood Flow Metab 1999, 19, 1263–1269. [Google Scholar]
  47. Vedder, H; Anthes, N; Stumm, G; Wurz, C; Behl, C; Krieg, JC. Estrogen hormones reduce lipid peroxidation in cells and tissues of the central nervous system. J. Neurochem 1999, 72, 2531–2538. [Google Scholar]
  48. Ayres, S; Abplanalp, W; Liu, JH; Subbiah, MT. Mechanisms involved in the protective effect of estradiol-17beta on lipid peroxidation and DNA damage. Am. J. Physiol 1998, 274, E1002–1008. [Google Scholar]
  49. Rattanajarasroj, S; Unchern, S. Comparable attenuation of Abeta(25–35)-induced neurotoxicity by quercitrin and 17beta-estradiol in cultured rat hippocampal neurons. Neurochem. Res 2010, 35, 1196–1205. [Google Scholar]
  50. Wang, X; Dykens, JA; Perez, E; Liu, R; Yang, S; Covey, DF; Simpkins, JW. Neuroprotective effects of 17beta-estradiol and nonfeminizing estrogens against H2O2 toxicity in human neuroblastoma SK-N-SH cells. Mol. Pharmacol 2006, 70, 395–404. [Google Scholar]
  51. Keller, JN; Germeyer, A; Begley, JG; Mattson, MP. 17Beta-estradiol attenuates oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport, and glutamate transport induced by amyloid beta-peptide and iron. J. Neurosci. Res 1997, 50, 522–530. [Google Scholar]
  52. Prokai, L; Simpkins, JW. Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds. Pharmacol. Ther 2007, 114, 1–12. [Google Scholar]
  53. Behl, C; Widmann, M; Trapp, T; Holsboer, F. 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun 1995, 216, 473–482. [Google Scholar]
  54. Bonnefont, AB; Munoz, FJ; Inestrosa, NC. Estrogen protects neuronal cells from the cytotoxicity induced by acetylcholinesterase-amyloid complexes. FEBS Lett 1998, 441, 220–224. [Google Scholar]
  55. Prokai, L; Prokai-Tatrai, K; Perjesi, P; Zharikova, AD; Perez, EJ; Liu, R; Simpkins, JW. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc. Natl. Acad. Sci. USA 2003, 100, 11741–11746. [Google Scholar]
  56. Prokai-Tatrai, K; Perjesi, P; Rivera-Portalatin, NM; Simpkins, JW; Prokai, L. Mechanistic investigations on the antioxidant action of a neuroprotective estrogen derivative. Steroids 2008, 73, 280–288. [Google Scholar]
  57. Picazo, O; Azcoitia, I; Garcia-Segura, LM. Neuroprotective and neurotoxic effects of estrogens. Brain Res 2003, 990, 20–27. [Google Scholar]
  58. Chen, C; Hu, Q; Yan, J; Lei, J; Qin, L; Shi, X; Luan, L; Yang, L; Wang, K; Han, J; Nanda, A; Zhou, C. Multiple effects of 2ME2 and D609 on the cortical expression of HIF-1alpha and apoptotic genes in a middle cerebral artery occlusion-induced focal ischemia rat model. J. Neurochem 2007, 102, 1831–1841. [Google Scholar]
  59. Bruce-Keller, AJ; Keeling, JL; Keller, JN; Huang, FF; Camondola, S; Mattson, MP. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 2000, 141, 3646–3656. [Google Scholar]
  60. Diwakar, L; Kenchappa, RS; Annepu, J; Ravindranath, V. Downregulation of glutaredoxin but not glutathione loss leads to mitochondrial dysfunction in female mice CNS: Implications in excitotoxicity. Neurochem. Int 2007, 51, 37–46. [Google Scholar]
  61. Schmidt, AJ; Krieg, JC; Vedder, H. Differential effects of glucocorticoids and gonadal steroids on glutathione levels in neuronal and glial cell systems. J. Neurosci. Res 2002, 67, 544–550. [Google Scholar]
  62. Diwakar, L; Kenchappa, RS; Annepu, J; Saeed, U; Sujanitha, R; Ravindranath, V. Down-regulation of glutaredoxin by estrogen receptor antagonist renders female mice susceptible to excitatory amino acid mediated complex I inhibition in CNS. Brain Res 2006, 1125, 176–184. [Google Scholar]
  63. Urata, Y; Ihara, Y; Murata, H; Goto, S; Koji, T; Yodoi, J; Inoue, S; Kondo, T. 17Beta-estradiol protects against oxidative stress-induced cell death through the glutathione/glutaredoxin-dependent redox regulation of Akt in myocardiac H9c2 cells. J. Biol. Chem 2006, 281, 13092–13102. [Google Scholar]
  64. Ozacmak, VH; Sayan, H. The effects of 17beta estradiol, 17alpha estradiol and progesterone on oxidative stress biomarkers in ovariectomized female rat brain subjected to global cerebral ischemia. Physiol. Res 2009, 58, 909–912. [Google Scholar]
  65. Gottipati, S; Cammarata, PR. Mitochondrial superoxide dismutase activation with 17 beta-estradiol-treated human lens epithelial cells. Mol. Vis 2008, 14, 898–905. [Google Scholar]
  66. Pedram, A; Razandi, M; Wallace, DC; Levin, ER. Functional estrogen receptors in the mitochondria of breast cancer cells. Mol. Biol. Cell 2006, 17, 2125–2137. [Google Scholar]
  67. Tripanichkul, W; Sripanichkulchai, K; Duce, JA; Finkelstein, DI. 17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult. Brain Res 2007, 1164, 24–31. [Google Scholar]
  68. Strehlow, K; Rotter, S; Wassmann, S; Adam, O; Grohe, C; Laufs, K; Bohm, M; Nickenig, G. Modulation of antioxidant enzyme expression and function by estrogen. Circ. Res 2003, 93, 170–177. [Google Scholar]
  69. Nilsen, J; Irwin, RW; Gallaher, TK; Brinton, RD. Estradiol in vivo regulation of brain mitochondrial proteome. J. Neurosci 2007, 27, 14069–14077. [Google Scholar]
  70. Irwin, RW; Yao, J; Hamilton, RT; Cadenas, E; Brinton, RD; Nilsen, J. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology 2008, 149, 3167–3175. [Google Scholar]
  71. Miller, AA; Drummond, GR; Mast, AE; Schmidt, HH; Sobey, CG. Effect of gender on NADPH-oxidase activity, expression, and function in the cerebral circulation: Role of estrogen. Stroke 2007, 38, 2142–2149. [Google Scholar]
  72. Zhang, QG; Raz, L; Wang, R; Han, D; De Sevilla, L; Yang, F; Vadlamudi, RK; Brann, DW. Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J. Neurosci 2009, 29, 13823–13836. [Google Scholar]
  73. Kumar, S; Lata, K; Mukhopadhyay, S; Mukherjee, TK. Role of estrogen receptors in pro-oxidative and anti-oxidative actions of estrogens: A perspective. Biochim. Biophys. Acta 2010, 1800, 1127–1135. [Google Scholar]
  74. Sastre-Serra, J; Valle, A; Company, MM; Garau, I; Oliver, J; Roca, P. Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic. Biol. Med 2010, 48, 506–512. [Google Scholar]
  75. Felty, Q; Xiong, WC; Sun, D; Sarkar, S; Singh, KP; Parkash, J; Roy, D. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry 2005, 44, 6900–6909. [Google Scholar]
  76. Rempel, MA; Hester, B; Deharo, H; Hong, H; Wang, Y; Schlenk, D. Effects of 17beta-estradiol, and its metabolite, 4-hydroxyestradiol on fertilization, embryo development and oxidative DNA damage in sand dollar (Dendraster excentricus) sperm. Sci. Total Environ 2009, 407, 2209–2215. [Google Scholar]
  77. Symonds, DA; Merchenthaler, I; Flaws, JA. Methoxychlor and estradiol induce oxidative stress DNA damage in the mouse ovarian surface epithelium. Toxicol. Sci 2008, 105, 182–187. [Google Scholar]
  78. Pajovic, SB; Saicic, ZS; Spasic, MB; Petrovic, VM. The effect of ovarian hormones on antioxidant enzyme activities in the brain of male rats. Physiol. Res 2003, 52, 189–194. [Google Scholar]
  79. Genc, S; Gurdol, F; Oner-Iyidogan, Y; Suzme, R. Acute effects of estradiol and of diethylstilbestrol: Pro- or antioxidant potential? Res. Commun. Mol. Pathol. Pharmacol 1999, 105, 253–261. [Google Scholar]
  80. Ting, CM; Lee, YM; Wong, CK; Wong, AS; Lung, HL; Lung, ML; Lo, KW; Wong, RN; Mak, NK. 2-Methoxyestradiol induces endoreduplication through the induction of mitochondrial oxidative stress and the activation of MAPK signaling pathways. Biochem. Pharmacol 2010, 79, 825–841. [Google Scholar]
  81. Park, SA; Na, HK; Kim, EH; Cha, YN; Surh, YJ. 4-hydroxyestradiol induces anchorage-independent growth of human mammary epithelial cells via activation of IkappaB kinase: potential role of reactive oxygen species. Cancer Res 2009, 69, 2416–2424. [Google Scholar]
  82. She, MR; Li, JG; Guo, KY; Lin, W; Du, X; Niu, XQ. Requirement of reactive oxygen species generation in apoptosis of leukemia cells induced by 2-methoxyestradiol. Acta Pharmacol. Sin 2007, 28, 1037–1044. [Google Scholar]
  83. Jin, R; Yang, G; Li, G. Inflammatory mechanisms in ischemic stroke: Role of inflammatory cells. J. Leukoc. Biol 2010, 87, 779–789. [Google Scholar]
  84. Barone, FC; Arvin, B; White, RF; Miller, A; Webb, CL; Willette, RN; Lysko, PG; Feuerstein, GZ. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 1997, 28, 1233–1244. [Google Scholar]
  85. Yamasaki, Y; Matsuura, N; Shozuhara, H; Onodera, H; Itoyama, Y; Kogure, K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995, 26, 676–680.discussion 681. [Google Scholar]
  86. Czlonkowska, A; Ciesielska, A; Gromadzka, G; Kurkowska-Jastrzebska, I. Gender differences in neurological disease: Role of estrogens and cytokines. Endocrine 2006, 29, 243–256. [Google Scholar]
  87. Mulcahy, NJ; Ross, J; Rothwell, NJ; Loddick, SA. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br. J. Pharmacol 2003, 140, 471–476. [Google Scholar]
  88. Relton, JK; Martin, D; Thompson, RC; Russell, DA. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp. Neurol 1996, 138, 206–213. [Google Scholar]
  89. Nawashiro, H; Martin, D; Hallenbeck, JM. Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. J. Cereb. Blood Flow Metab 1997, 17, 229–232. [Google Scholar]
  90. Martin-Villalba, A; Hahne, M; Kleber, S; Vogel, J; Falk, W; Schenkel, J; Krammer, PH. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001, 8, 679–686. [Google Scholar]
  91. Loddick, SA; Rothwell, NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J. Cereb. Blood Flow Metab 1996, 16, 932–940. [Google Scholar]
  92. Santizo, RA; Anderson, S; Ye, S; Koenig, HM; Pelligrino, DA. Effects of estrogen on leukocyte adhesion after transient forebrain ischemia. Stroke 2000, 31, 2231–2235. [Google Scholar]
  93. Mori, M; Tsukahara, F; Yoshioka, T; Irie, K; Ohta, H. Suppression by 17beta-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors. Life Sci 2004, 75, 599–609. [Google Scholar]
  94. Nathan, L; Pervin, S; Singh, R; Rosenfeld, M; Chaudhuri, G. Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo: Possible mechanisms for gender differences in atherosclerosis. Circ. Res 1999, 85, 377–385. [Google Scholar]
  95. Suzuki, S; Brown, CM; Dela Cruz, CD; Yang, E; Bridwell, DA; Wise, PM. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc. Natl. Acad. Sci. USA 2007, 104, 6013–6018. [Google Scholar]
  96. Chiappetta, O; Gliozzi, M; Siviglia, E; Amantea, D; Morrone, LA; Berliocchi, L; Bagetta, G; Corasaniti, MT. Evidence to implicate early modulation of interleukin-1beta expression in the neuroprotection afforded by 17beta-estradiol in male rats undergone transient middle cerebral artery occlusion. Int. Rev. Neurobiol 2007, 82, 357–372. [Google Scholar]
  97. Nordell, VL; Scarborough, MM; Buchanan, AK; Sohrabji, F. Differential effects of estrogen in the injured forebrain of young adult and reproductive senescent animals. Neurobiol. Aging 2003, 24, 733–743. [Google Scholar]
  98. Tenenbaum, M; Azab, AN; Kaplanski, J. Effects of estrogen against LPS-induced inflammation and toxicity in primary rat glial and neuronal cultures. J. Endotoxin Res 2007, 13, 158–166. [Google Scholar]
  99. Vegeto, E; Bonincontro, C; Pollio, G; Sala, A; Viappiani, S; Nardi, F; Brusadelli, A; Viviani, B; Ciana, P; Maggi, A. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J. Neurosci 2001, 21, 1809–1818. [Google Scholar]
  100. Lewis, DK; Johnson, AB; Stohlgren, S; Harms, A; Sohrabji, F. Effects of estrogen receptor agonists on regulation of the inflammatory response in astrocytes from young adult and middle-aged female rats. J. Neuroimmunol 2008, 195, 47–59. [Google Scholar]
  101. Ray, P; Ghosh, SK; Zhang, DH; Ray, A. Repression of interleukin-6 gene expression by 17beta-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett 1997, 409, 79–85. [Google Scholar]
  102. Ospina, JA; Brevig, HN; Krause, DN; Duckles, SP. Estrogen suppresses IL-1beta-mediated induction of COX-2 pathway in rat cerebral blood vessels. Am. J. Physiol. Heart Circ. Physiol 2004, 286, H2010–2019. [Google Scholar]
  103. Vegeto, E; Belcredito, S; Etteri, S; Ghisletti, S; Brusadelli, A; Meda, C; Krust, A; Dupont, S; Ciana, P; Chambon, P; Maggi, A. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc. Natl. Acad. Sci. USA 2003, 100, 9614–9619. [Google Scholar]
  104. Vegeto, E; Benedusi, V; Maggi, A. Estrogen anti-inflammatory activity in brain: A therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol 2008, 29, 507–519. [Google Scholar]
  105. Sunday, L; Osuna, C; Krause, DN; Duckles, SP. Age alters cerebrovascular inflammation and effects of estrogen. Am. J. Physiol. Heart Circ. Physiol 2007, 292, H2333–2340. [Google Scholar]
  106. Srivastava, S; Weitzmann, MN; Cenci, S; Ross, FP; Adler, S; Pacifici, R. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J. Clin. Invest 1999, 104, 503–513. [Google Scholar]
  107. Yatkin, E; Bernoulli, J; Talvitie, EM; Santti, R. Inflammation and epithelial alterations in rat prostate: Impact of the androgen to oestrogen ratio. Int. J. Androl 2009, 32, 399–410. [Google Scholar]
  108. Salem, ML; Hossain, MS; Nomoto, K. Mediation of the immunomodulatory effect of beta-estradiol on inflammatory responses by inhibition of recruitment and activation of inflammatory cells and their gene expression of TNF-alpha and IFN-gamma. Int. Arch. Allergy Immunol 2000, 121, 235–245. [Google Scholar]
  109. Wen, Y; Yang, S; Liu, R; Perez, E; Yi, KD; Koulen, P; Simpkins, JW. Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res 2004, 1008, 147–154. [Google Scholar]
  110. Lei, DL; Long, JM; Hengemihle, J; O’Neill, J; Manaye, KF; Ingram, DK; Mouton, PR. Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampus of aged female mice. Neuroscience 2003, 121, 659–666. [Google Scholar]
  111. Brown, CM; Dela Cruz, CD; Yang, E; Wise, PM. Inducible nitric oxide synthase and estradiol exhibit complementary neuroprotective roles after ischemic brain injury. Exp. Neurol 2008, 210, 782–787. [Google Scholar]
  112. Park, EM; Cho, S; Frys, KA; Glickstein, SB; Zhou, P; Anrather, J; Ross, ME; Iadecola, C. Inducible nitric oxide synthase contributes to gender differences in ischemic brain injury. J. Cereb. Blood Flow Metab 2006, 26, 392–401. [Google Scholar]
  113. Xu, HL; Baughman, VL; Pelligrino, DA. Estrogen replacement treatment in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules. Stroke 2004, 35, 1974–1978. [Google Scholar]
  114. Soucy, G; Boivin, G; Labrie, F; Rivest, S. Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J. Immunol 2005, 174, 6391–6398. [Google Scholar]
  115. Johnson, AB; Sohrabji, F. Estrogen’s effects on central and circulating immune cells vary with reproductive age. Neurobiol. Aging 2005, 26, 1365–1374. [Google Scholar]
  116. Marriott, LK; Hauss-Wegrzyniak, B; Benton, RS; Vraniak, PD; Wenk, GL. Long-term estrogen therapy worsens the behavioral and neuropathological consequences of chronic brain inflammation. Behav. Neurosci 2002, 116, 902–911. [Google Scholar]
  117. O’Donnell, ME; Lam, TI; Tran, LQ; Foroutan, S; Anderson, SE. Estradiol reduces activity of the blood-brain barrier Na-K-Cl cotransporter and decreases edema formation in permanent middle cerebral artery occlusion. J. Cereb. Blood Flow Metab 2006, 26, 1234–1249. [Google Scholar]
  118. Krause, DN; Duckles, SP; Pelligrino, DA. Influence of sex steroid hormones on cerebrovascular function. J. Appl. Physiol 2006, 101, 1252–1261. [Google Scholar]
  119. Wise, PM; Dubal, DB. Estradiol protects against ischemic brain injury in middle-aged rats. Biol. Reprod 2000, 63, 982–985. [Google Scholar]
  120. Dubal, DB; Wise, PM. Neuroprotective effects of estradiol in middle-aged female rats. Endocrinology 2001, 142, 43–48. [Google Scholar]
  121. Toung, TJ; Chen, TY; Littleton-Kearney, MT; Hurn, PD; Murphy, SJ. Effects of combined estrogen and progesterone on brain infarction in reproductively senescent female rats. J. Cereb. Blood Flow Metab 2004, 24, 1160–1166. [Google Scholar]
  122. Alkayed, NJ; Murphy, SJ; Traystman, RJ; Hurn, PD; Miller, VM. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke 2000, 31, 161–168. [Google Scholar]
  123. Toung, TK; Hurn, PD; Traystman, RJ; Sieber, FE. Estrogen decreases infarct size after temporary focal ischemia in a genetic model of type 1 diabetes mellitus. Stroke 2000, 31, 2701–2706. [Google Scholar]
  124. Brouns, R; De Deyn, PP. The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosurg 2009, 111, 483–495. [Google Scholar]
  125. Brann, DW; Zamorano, PL; Chorich, LP; Mahesh, VB. Steroid hormone effects on NMDA receptor binding and NMDA receptor mRNA levels in the hypothalamus and cerebral cortex of the adult rat. Neuroendocrinology 1993, 58, 666–672. [Google Scholar]
  126. Woolley, CS; Weiland, NG; McEwen, BS; Schwartzkroin, PA. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: Correlation with dendritic spine density. J. Neurosci 1997, 17, 1848–1859. [Google Scholar]
  127. Weiland, NG. Estradiol selectively regulates agonist binding sites on the N-methyl-D-aspartate receptor complex in the CA1 region of the hippocampus. Endocrinology 1992, 131, 662–668. [Google Scholar]
  128. Woolley, CS; McEwen, BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J. Comp. Neurol 1993, 336, 293–306. [Google Scholar]
  129. Woolley, CS; McEwen, BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J. Neurosci 1992, 12, 2549–2554. [Google Scholar]
  130. Pozzo-Miller, LD; Inoue, T; Murphy, DD. Estradiol increases spine density and NMDA-dependent Ca2+ transients in spines of CA1 pyramidal neurons from hippocampal slices. J. Neurophysiol 1999, 81, 1404–1411. [Google Scholar]
  131. Buterbaugh, GG; Hudson, GM. Estradiol replacement to female rats facilitates dorsal hippocampal but not ventral hippocampal kindled seizure acquisition. Exp. Neurol 1991, 111, 55–64. [Google Scholar]
  132. Warren, SG; Humphreys, AG; Juraska, JM; Greenough, WT. LTP varies across the estrous cycle: enhanced synaptic plasticity in proestrus rats. Brain Res 1995, 703, 26–30. [Google Scholar]
  133. Foy, MR; Xu, J; Xie, X; Brinton, RD; Thompson, RF; Berger, TW. 17Beta-estradiol enhances NMDA receptor-mediated EPSPs and long-term potentiation. J. Neurophysiol 1999, 81, 925–929. [Google Scholar]
  134. Teyler, TJ; Vardaris, RM; Lewis, D; Rawitch, AB. Gonadal steroids: Effects on excitability of hippocampal pyramidal cells. Science 1980, 209, 1017–1018. [Google Scholar]
  135. Smith, SS; Waterhouse, BD; Woodward, DJ. Sex steroid effects on extrahypothalamic CNS. I. Estrogen augments neuronal responsiveness to iontophoretically applied glutamate in the cerebellum. Brain Res 1987, 422, 40–51. [Google Scholar]
  136. Sato, K; Matsuki, N; Ohno, Y; Nakazawa, K. Estrogens inhibit l-glutamate uptake activity of astrocytes via membrane estrogen receptor alpha. J. Neurochem 2003, 86, 1498–1505. [Google Scholar]
  137. Gu, Q; Moss, RL. 17Beta-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. J. Neurosci 1996, 16, 3620–3629. [Google Scholar]
  138. Johansen, FF; Jorgensen, MB; Diemer, NH. Ischemic CA-1 pyramidal cell loss is prevented by preischemic colchicine destruction of dentate gyrus granule cells. Brain Res 1986, 377, 344–347. [Google Scholar]
  139. Onodera, H; Sato, G; Kogure, K. Lesions to Schaffer collaterals prevent ischemic death of CA1 pyramidal cells. Neurosci. Lett 1986, 68, 169–174. [Google Scholar]
  140. Wieloch, T; Lindvall, O; Blomqvist, P; Gage, FH. Evidence for amelioration of ischaemic neuronal damage in the hippocampal formation by lesions of the perforant path. Neurol. Res 1985, 7, 24–26. [Google Scholar]
  141. Ito, H; Watanabe, Y; Isshiki, A; Uchino, H. Neuroprotective properties of propofol and midazolam, but not pentobarbital, on neuronal damage induced by forebrain ischemia, based on the GABAA receptors. Acta Anaesthesiol. Scand 1999, 43, 153–162. [Google Scholar]
  142. Schwartz-Bloom, RD; McDonough, KJ; Chase, PJ; Chadwick, LE; Inglefield, JR; Levin, ED. Long-term neuroprotection by benzodiazepine full versus partial agonists after transient cerebral ischemia in the gerbil [corrected]. J. Cereb. Blood Flow Metab 1998, 18, 548–558. [Google Scholar]
  143. Goodman, Y; Bruce, AJ; Cheng, B; Mattson, MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem 1996, 66, 1836–1844. [Google Scholar]
  144. Azcoitia, I; Fernandez-Galaz, C; Sierra, A; Garcia-Segura, LM. Gonadal hormones affect neuronal vulnerability to excitotoxin-induced degeneration. J. Neurocytol 1999, 28, 699–710. [Google Scholar]
  145. Mendelowitsch, A; Ritz, MF; Ros, J; Langemann, H; Gratzl, O. 17beta-Estradiol reduces cortical lesion size in the glutamate excitotoxicity model by enhancing extracellular lactate: A new neuroprotective pathway. Brain Res 2001, 901, 230–236. [Google Scholar]
  146. DeGiorgio, LA; Attardi, B; Shimizu, Y; Ogata, M; Volpe, BT. 17Beta-estradiol treatment retards excitotoxic delayed degeneration in substantia nigra reticulata neurons. Brain Res 2002, 936, 15–20. [Google Scholar]
  147. Ritz, MF; Schmidt, P; Mendelowitsch, A. 17Beta-estradiol effect on the extracellular concentration of amino acids in the glutamate excitotoxicity model in the rat. Neurochem. Res 2002, 27, 1677–1683. [Google Scholar]
  148. Ritz, MF; Schmidt, P; Mendelowitsch, A. Acute effects of 17beta-estradiol on the extracellular concentration of excitatory amino acids and energy metabolites during transient cerebral ischemia in male rats. Brain Res 2004, 1022, 157–163. [Google Scholar]
  149. Zhang, H; Xie, M; Schools, GP; Feustel, PF; Wang, W; Lei, T; Kimelberg, HK; Zhou, M. Tamoxifen mediated estrogen receptor activation protects against early impairment of hippocampal neuron excitability in an oxygen/glucose deprivation brain slice ischemia model. Brain Res 2009, 1247, 196–211. [Google Scholar]
  150. Zhang, F; Yin, W; Chen, J. Apoptosis in cerebral ischemia: Executional and regulatory signaling mechanisms. Neurol. Res 2004, 26, 835–845. [Google Scholar]
  151. Niizuma, K; Yoshioka, H; Chen, H; Kim, GS; Jung, JE; Katsu, M; Okami, N; Chan, PH. Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia. Biochim. Biophys. Acta 2010, 1802, 92–99. [Google Scholar]
  152. Broughton, BR; Reutens, DC; Sobey, CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009, 40, e331–339. [Google Scholar]
  153. Estus, S; Tucker, HM; van Rooyen, C; Wright, S; Brigham, EF; Wogulis, M; Rydel, RE. Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant “apoptotic” pattern of gene induction. J. Neurosci 1997, 17, 7736–7745. [Google Scholar]
  154. Estus, S; Zaks, WJ; Freeman, RS; Gruda, M; Bravo, R; Johnson, EM, Jr. Altered gene expression in neurons during programmed cell death: Identification of c-jun as necessary for neuronal apoptosis. J. Cell Biol 1994, 127, 1717–1727. [Google Scholar]
  155. Rau, SW; Dubal, DB; Bottner, M; Wise, PM. Estradiol differentially regulates c-Fos after focal cerebral ischemia. J. Neurosci 2003, 23, 10487–10494. [Google Scholar]
  156. Kitagawa, K; Matsumoto, M; Tsujimoto, Y; Ohtsuki, T; Kuwabara, K; Matsushita, K; Yang, G; Tanabe, H; Martinou, JC; Hori, M; Yanagihara, T. Amelioration of hippocampal neuronal damage after global ischemia by neuronal overexpression of BCL-2 in transgenic mice. Stroke 1998, 29, 2616–2621. [Google Scholar]
  157. Alkayed, NJ; Goto, S; Sugo, N; Joh, HD; Klaus, J; Crain, BJ; Bernard, O; Traystman, RJ; Hurn, PD. Estrogen and Bcl-2: Gene induction and effect of transgene in experimental stroke. J. Neurosci 2001, 21, 7543–7550. [Google Scholar]
  158. Krajewski, S; Mai, JK; Krajewska, M; Sikorska, M; Mossakowski, MJ; Reed, JC. Upregulation of bax protein levels in neurons following cerebral ischemia. J. Neurosci 1995, 15, 6364–6376. [Google Scholar]
  159. Dubal, DB; Shughrue, PJ; Wilson, ME; Merchenthaler, I; Wise, PM. Estradiol modulates bcl-2 in cerebral ischemia: A potential role for estrogen receptors. J. Neurosci 1999, 19, 6385–6393. [Google Scholar]
  160. Jover, T; Tanaka, H; Calderone, A; Oguro, K; Bennett, MV; Etgen, AM; Zukin, RS. Estrogen protects against global ischemia-induced neuronal death and prevents activation of apoptotic signaling cascades in the hippocampal CA1. J. Neurosci 2002, 22, 2115–2124. [Google Scholar]
  161. Pike, CJ. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: Relevance to Alzheimer’s disease. J. Neurochem 1999, 72, 1552–1563. [Google Scholar]
  162. Singer, CA; Rogers, KL; Dorsa, DM. Modulation of Bcl-2 expression: A potential component of estrogen protection in NT2 neurons. Neuroreport 1998, 9, 2565–2568. [Google Scholar]
  163. Kandouz, M; Siromachkova, M; Jacob, D; Chretien Marquet, B; Therwath, A; Gompel, A. Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. Int. J. Cancer 1996, 68, 120–125. [Google Scholar]
  164. Yune, TY; Park, HG; Lee, JY; Oh, TH. Estrogen-induced Bcl-2 expression after spinal cord injury is mediated through phosphoinositide-3-kinase/Akt-dependent CREB activation. J. Neurotrauma 2008, 25, 1121–1131. [Google Scholar]
  165. Fan, L; Pandey, SC; Cohen, RS. Estrogen affects levels of Bcl-2 protein and mRNA in medial amygdala of ovariectomized rats. J. Neurosci. Res 2008, 86, 3655–3664. [Google Scholar]
  166. Sharma, K; Mehra, RD. Long-term administration of estrogen or tamoxifen to ovariectomized rats affords neuroprotection to hippocampal neurons by modulating the expression of Bcl-2 and Bax. Brain Res 2008, 1204, 1–15. [Google Scholar]
  167. Gollapudi, L; Oblinger, MM. Estrogen and NGF synergistically protect terminally differentiated, ERalpha-transfected PC12 cells from apoptosis. J. Neurosci. Res 1999, 56, 471–481. [Google Scholar]
  168. Honda, K; Shimohama, S; Sawada, H; Kihara, T; Nakamizo, T; Shibasaki, H; Akaike, A. Nongenomic antiapoptotic signal transduction by estrogen in cultured cortical neurons. J. Neurosci. Res 2001, 64, 466–475. [Google Scholar]
  169. Lee, SY; Andoh, T; Murphy, DL; Chiueh, CC. 17Beta-estradiol activates ICI 182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection. FASEB J 2003, 17, 947–948. [Google Scholar]
  170. Zhang, Y; Bhavnani, BR. Glutamate-induced apoptosis in primary cortical neurons is inhibited by equine estrogens via down-regulation of caspase-3 and prevention of mitochondrial cytochrome c release. BMC Neurosci 2005, 6, 13. [Google Scholar]
  171. Teixeira, C; Reed, JC; Pratt, MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995, 55, 3902–3907. [Google Scholar]
  172. Funakoshi, T; Yanai, A; Shinoda, K; Kawano, MM; Mizukami, Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem. Biophys. Res. Commun 2006, 346, 904–910. [Google Scholar]
  173. Simpkins, JW; Wang, J; Wang, X; Perez, E; Prokai, L; Dykens, JA. Mitochondria play a central role in estrogen-induced neuroprotection. Curr. Drug. Targets CNS Neurol. Disord 2005, 4, 69–83. [Google Scholar]
  174. Hansen, TM; Moss, AJ; Brindle, NP. Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke. Curr. Neurovasc. Res 2008, 5, 236–245. [Google Scholar]
  175. Garcia-Segura, LM; Azcoitia, I; DonCarlos, LL. Neuroprotection by estradiol. Prog. Neurobiol 2001, 63, 29–60. [Google Scholar]
  176. Jones, KJ. Gonadal steroids as promoting factors in axonal regeneration. Brain Res. Bull 1993, 30, 491–498. [Google Scholar]
  177. Garcia-Segura, LM; Sanz, A; Mendez, P. Cross-talk between IGF-I and estradiol in the brain: Focus on neuroprotection. Neuroendocrinology 2006, 84, 275–279. [Google Scholar]
  178. Duenas, M; Luquin, S; Chowen, JA; Torres-Aleman, I; Naftolin, F; Garcia-Segura, LM. Gonadal hormone regulation of insulin-like growth factor-I-like immunoreactivity in hypothalamic astroglia of developing and adult rats. Neuroendocrinology 1994, 59, 528–538. [Google Scholar]
  179. Jezierski, MK; Sohrabji, F. Region- and peptide-specific regulation of the neurotrophins by estrogen. Brain Res. Mol. Brain Res 2000, 85, 77–84. [Google Scholar]
  180. Gibbs, RB. Treatment with estrogen and progesterone affects relative levels of brain-derived neurotrophic factor mRNA and protein in different regions of the adult rat brain. Brain Res 1999, 844, 20–27. [Google Scholar]
  181. Sohrabji, F; Miranda, RC; Toran-Allerand, CD. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. USA 1995, 92, 11110–11114. [Google Scholar]
  182. Dhandapani, KM; Wade, FM; Mahesh, VB; Brann, DW. Astrocyte-derived transforming growth factor-{beta} mediates the neuroprotective effects of 17{beta}-estradiol: Involvement of nonclassical genomic signaling pathways. Endocrinology 2005, 146, 2749–2759. [Google Scholar]
  183. Mueller, MD; Vigne, JL; Minchenko, A; Lebovic, DI; Leitman, DC; Taylor, RN. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc. Natl. Acad. Sci. USA 2000, 97, 10972–10977. [Google Scholar]
  184. El-Ashry, D; Chrysogelos, SA; Lippman, ME; Kern, FG. Estrogen induction of TGF-alpha is mediated by an estrogen response element composed of two imperfect palindromes. J. Steroid Biochem. Mol. Biol 1996, 59, 261–269. [Google Scholar]
  185. Ferreira, A; Caceres, A. Estrogen-enhanced neurite growth: Evidence for a selective induction of Tau and stable microtubules. J. Neurosci 1991, 11, 392–400. [Google Scholar]
  186. Singh, M; Setalo, G, Jr; Guan, X; Frail, DE; Toran-Allerand, CD. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-alpha knock-out mice. J. Neurosci 2000, 20, 1694–1700. [Google Scholar]
  187. Mendez, P; Azcoitia, I; Garcia-Segura, LM. Estrogen receptor alpha forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain. Brain Res. Mol. Brain Res 2003, 112, 170–176. [Google Scholar]
  188. Quesada, A; Micevych, PE. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J. Neurosci. Res 2004, 75, 107–116. [Google Scholar]
  189. Azcoitia, I; Sierra, A; Garcia-Segura, LM. Neuroprotective effects of estradiol in the adult rat hippocampus: Interaction with insulin-like growth factor-I signalling. J. Neurosci. Res 1999, 58, 815–822. [Google Scholar]
  190. Jover-Mengual, T; Zukin, RS; Etgen, AM. MAPK signaling is critical to estradiol protection of CA1 neurons in global ischemia. Endocrinology 2007, 148, 1131–1143. [Google Scholar]
  191. Traub, ML; De Butte-Smith, M; Zukin, RS; Etgen, AM. Oestradiol and insulin-like growth factor-1 reduce cell loss after global ischaemia in middle-aged female rats. J. Neuroendocrinol 2009, 21, 1038–1044. [Google Scholar]
  192. Shughrue, PJ; Dorsa, DM. Estrogen modulates the growth-associated protein GAP-43 (Neuromodulin) mRNA in the rat preoptic area and basal hypothalamus. Neuroendocrinology 1993, 57, 439–447. [Google Scholar]
  193. Teter, B; Harris-White, ME; Frautschy, SA; Cole, GM. Role of apolipoprotein E and estrogen in mossy fiber sprouting in hippocampal slice cultures. Neuroscience 1999, 91, 1009–1016. [Google Scholar]
  194. Scoville, SA; Bufton, SM; Liuzzi, FJ. Estrogen regulates neurofilament gene expression in adult female rat dorsal root ganglion neurons. Exp. Neurol 1997, 146, 596–599. [Google Scholar]
  195. Salom, JB; Burguete, MC; Perez-Asensio, FJ; Torregrosa, G; Alborch, E. Relaxant effects of 17-beta-estradiol in cerebral arteries through Ca(2+) entry inhibition. J. Cereb. Blood Flow Metab 2001, 21, 422–429. [Google Scholar]
  196. Ono, H; Sasaki, Y; Bamba, E; Seki, J; Giddings, JC; Yamamoto, J. Cerebral thrombosis and microcirculation of the rat during the oestrous cycle and after ovariectomy. Clin. Exp. Pharmacol. Physiol 2002, 29, 73–78. [Google Scholar]
  197. Ospina, JA; Krause, DN; Duckles, SP. 17Beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 2002, 33, 600–605. [Google Scholar]
  198. Ospina, JA; Duckles, SP; Krause, DN. 17Beta-estradiol decreases vascular tone in cerebral arteries by shifting COX-dependent vasoconstriction to vasodilation. Am. J. Physiol. Heart Circ. Physiol 2003, 285, H241–250. [Google Scholar]
  199. Momoi, H; Ikomi, F; Ohhashi, T. Estrogen-induced augmentation of endothelium-dependent nitric oxide-mediated vasodilation in isolated rat cerebral small arteries. Jpn. J. Physiol 2003, 53, 193–203. [Google Scholar]
  200. Geary, GG; McNeill, AM; Ospina, JA; Krause, DN; Korach, KS; Duckles, SP. Selected contribution: Cerebrovascular nos and cyclooxygenase are unaffected by estrogen in mice lacking estrogen receptor-alpha. J Appl Physiol 2001, 91, 2391–2399.discussion 2389–2390. [Google Scholar]
  201. McNeill, AM; Kim, N; Duckles, SP; Krause, DN; Kontos, HA. Chronic estrogen treatment increases levels of endothelial nitric oxide synthase protein in rat cerebral microvessels. Stroke 1999, 30, 2186–2190. [Google Scholar]
  202. Geary, GG; Krause, DN; Duckles, SP. Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms. Am. J. Physiol. Heart Circ. Physiol 2000, 279, H610–618. [Google Scholar]
  203. Pelligrino, DA; Ye, S; Tan, F; Santizo, RA; Feinstein, DL; Wang, Q. Nitric-oxide-dependent pial arteriolar dilation in the female rat: Effects of chronic estrogen depletion and repletion. Biochem. Biophys. Res. Commun 2000, 269, 165–171. [Google Scholar]
  204. Stirone, C; Chu, Y; Sunday, L; Duckles, SP; Krause, DN. 17Beta-estradiol increases endothelial nitric oxide synthase mRNA copy number in cerebral blood vessels: Quantification by real-time polymerase chain reaction. Eur. J. Pharmacol 2003, 478, 35–38. [Google Scholar]
  205. Geary, GG; Krause, DN; Duckles, SP. Estrogen reduces myogenic tone through a nitric oxide-dependent mechanism in rat cerebral arteries. Am. J. Physiol 1998, 275, H292–300. [Google Scholar]
  206. Geary, GG; Krause, DN; Duckles, SP. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am. J. Physiol. Heart Circ. Physiol 2000, 279, H511–519. [Google Scholar]
  207. Skarsgard, P; van Breemen, C; Laher, I. Estrogen regulates myogenic tone in pressurized cerebral arteries by enhanced basal release of nitric oxide. Am. J. Physiol 1997, 273, H2248–2256. [Google Scholar]
  208. Sobey, CG; Weiler, JM; Boujaoude, M; Woodman, OL. Effect of short-term phytoestrogen treatment in male rats on nitric oxide-mediated responses of carotid and cerebral arteries: Comparison with 17beta-estradiol. J. Pharmacol. Exp. Ther 2004, 310, 135–140. [Google Scholar]
  209. Alkayed, NJ; Harukuni, I; Kimes, AS; London, ED; Traystman, RJ; Hurn, PD. Gender-linked brain injury in experimental stroke. Stroke 1998, 29, 159–165.discussion 166. [Google Scholar]
  210. Krejza, J; Siemkowicz, J; Sawicka, M; Szylak, A; Kochanowicz, J; Mariak, Z; Lewko, J; Spektor, V; Babikian, V; Bert, R. Oscillations of cerebrovascular resistance throughout the menstrual cycle in healthy women. Ultrasound Obstet. Gynecol 2003, 22, 627–632. [Google Scholar]
  211. McCullough, LD; Alkayed, NJ; Traystman, RJ; Williams, MJ; Hurn, PD. Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. Stroke 2001, 32, 796–802. [Google Scholar]
  212. Watanabe, Y; Littleton-Kearney, MT; Traystman, RJ; Hurn, PD. Estrogen restores postischemic pial microvascular dilation. Am. J. Physiol. Heart Circ. Physiol 2001, 281, H155–160. [Google Scholar]
  213. Coma, M; Guix, FX; Uribesalgo, I; Espuna, G; Sole, M; Andreu, D; Munoz, FJ. Lack of oestrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination. Brain 2005, 128, 1613–1621. [Google Scholar]
  214. Radi, R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc. Natl. Acad. Sci. USA 2004, 101, 4003–4008. [Google Scholar]
  215. Wang, Q; Santizo, R; Baughman, VL; Pelligrino, DA; Iadecola, C. Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats. Stroke 1999, 30, 630–637. [Google Scholar]
  216. Carswell, HV; Anderson, NH; Morton, JJ; McCulloch, J; Dominiczak, AF; Macrae, IM. Investigation of estrogen status and increased stroke sensitivity on cerebral blood flow after a focal ischemic insult. J. Cereb. Blood Flow Metab 2000, 20, 931–936. [Google Scholar]
  217. Shi, J; Bui, JD; Yang, SH; He, Z; Lucas, TH; Buckley, DL; Blackband, SJ; King, MA; Day, AL; Simpkins, JW. Estrogens decrease reperfusion-associated cortical ischemic damage: An MRI analysis in a transient focal ischemia model. Stroke 2001, 32, 987–992. [Google Scholar]
  218. Rusa, R; Alkayed, NJ; Crain, BJ; Traystman, RJ; Kimes, AS; London, ED; Klaus, JA; Hurn, PD. 17Beta-estradiol reduces stroke injury in estrogen-deficient female animals. Stroke 1999, 30, 1665–1670. [Google Scholar]
  219. Choi, JM; Romeo, RD; Brake, WG; Bethea, CL; Rosenwaks, Z; McEwen, BS. Estradiol increases pre- and post-synaptic proteins in the CA1 region of the hippocampus in female rhesus macaques (Macaca mulatta). Endocrinology 2003, 144, 4734–4738. [Google Scholar]
Ijms 12 01533f1 1024
Figure 1. A simplified map of suggested pathways and mechanisms for estrogens’ effects in stroke. Orange and blue rectangles mark plausibly detrimental and protective effects, respectively. The balance in the background symbolizes that depending on the circumstances, such as the dose of estrogen, either the protective or detrimental mechanisms may dominate. The “E” in the middle of the figure is short for “Estrogens” (other abbreviations are detailed above the Introduction). Depicted pathways and mechanisms have previously been reviewed in numerous publications [12,13,34,3743]. Each part of the figure is matched with exact citations in respective sections throughout the article.

Click here to enlarge figure

Figure 1. A simplified map of suggested pathways and mechanisms for estrogens’ effects in stroke. Orange and blue rectangles mark plausibly detrimental and protective effects, respectively. The balance in the background symbolizes that depending on the circumstances, such as the dose of estrogen, either the protective or detrimental mechanisms may dominate. The “E” in the middle of the figure is short for “Estrogens” (other abbreviations are detailed above the Introduction). Depicted pathways and mechanisms have previously been reviewed in numerous publications [12,13,34,3743]. Each part of the figure is matched with exact citations in respective sections throughout the article.
Ijms 12 01533f1 1024
Table Table 1. Administration method dose ranges in relation to neuroprotection and neurodamage. 17β-estradiol doses and capsule concentration ranges reported to induce neuroprotection and neurodamage, respectively, in rat models of cerebral ischemia. For injection regimens, daily doses are presented. Silastic capsules containing crystallized estrogen are omitted from the table, but were consistently neuroprotective [15].

Click here to display table

Table 1. Administration method dose ranges in relation to neuroprotection and neurodamage. 17β-estradiol doses and capsule concentration ranges reported to induce neuroprotection and neurodamage, respectively, in rat models of cerebral ischemia. For injection regimens, daily doses are presented. Silastic capsules containing crystallized estrogen are omitted from the table, but were consistently neuroprotective [15].
Administration methodPellet dose/silastic capsule concentration/injection dose ranges
NeuroprotectionNeurodamage
Slow-release pellets, subcutaneous0.025–0.25 mg [19,20]0.025–1.5 mg [6,8]
Silastic capsules filled with 17β-estradiol dissolved in oil, subcutaneous180–4000 μg/mL [21,22]Not reported
Injections, subcutaneous10–5000 μg/kg BW [23,24]Not reported
Injection, intravenous10–1000 μg/kg BW [2,25]Not reported
Injection, intraperitoneal100–20,000 μg/kg BW [26,27]Not reported
Injection, intramuscular100 μg/kg BW [28]Not reported
Infusion, intraventricular50–150 μg [29,30]Not reported
Oral administration10 μg/kg BW [31]Not reported
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert